PT  - JOURNAL ARTICLE
AU  - Roy T.M. Sprooten
AU  - Bettine A.H. Vosse
AU  - Anne Q.R. Visser
AU  - Sander C.M. Steyns
AU  - Marijke Rutten
AU  - Nicolle A.M. Cobben
AU  - Geertjan Wesseling
TI  - 1-Year mortality in patients with home mechanical ventilation
AID  - 10.1183/13993003.congress-2020.3412
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 3412
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/3412.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/3412.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: Knowledge about long-term outcome in patients using home mechanical ventilation (HMV) is important to optimize shared decision making and advanced care planning. This study is aimed to assess the 1-year overall mortality and to identify its predictors in patients starting with HMV.Methods: Patients who started HMV in our centre between January 1, 2012–December 31, 2017 were included. Data on demographics, diagnosis, blood gasses and lung function were assessed as well as the Severe Respiratory Insufficiency (SRI) questionnaire and Care Dependency Scale (CDS). Univariate and multivariate logistic regression were used for statistical analysis.Results: The 1-year overall mortality in 812 adults (mean age 63 years [range 53-70]) was 20%. Classified by disease category, the mortality was respectively 48%, 21%, 10%, 8% and 7% in rapidly progressive neuromuscular disease (NMD), end-stage lung diseases/Chronic Obstructive Pulmonary Disease (ELD/COPD), slowly progressive NMD and thoracic deformities, myotonic dystrophy type 1 and sleep disorders. Independent predictors for mortality were: age (odds ratio (OR) 1.033 [confidential interval (CI)] 1.014-1.053), diagnosis category (OR 3.433 [CI] 2.207-5.339), base excess (BE)>4 (OR 0.599 [CI] 0.370-0.970), peak expiratory flow (PEF) (OR 0.998 [CI] 0.996-1.000), CDS (OR 0.968 [CI] 0.945-0.992), SRI total (OR 1.162 [CI] 1.033-1.307), SRI respiratory complaints (RC) (OR 0.951 [CI] 0.915-0.989), SRI mental well-being (WB) (OR 0.955 [CI] 0.922-0.990).Method: The 1-year overall mortality in patients starting HMV is 20% and the highest in rapidly progressive NMD and in ELD/COPD. Survival was strongly related to age, diagnosis, BE>4, PEF, CDS, SRI-total, SRI-RC, SRI-WB.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3412.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).